Resource Summary Report

Generated by RRID on Aug 25, 2026

pY011 (pcDNA3.1-hLb2Cpf1)

RRID:Addgene_69983
Type: Plasmid

Proper Citation

RRID:Addgene_69983

Plasmid Information

URL: http://www.addgene.org/69983

Proper Citation: RRID:Addgene_69983

Insert Name: hLb2Cpf1

Organism: Lachnospiraceae_bacterium_MA2020

Bacterial Resistance: Ampicillin

Defining Citation: PMID:26422227

Vector Backbone Description: Backbone Size:5354; Vector Backbone:pcDNA3.1; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: pY011 (pcDNA3.1-hLb2Cpf1)

Record Creation Time: 20220422T222433+0000

Record Last Update: 20260815T081857+0000

Ratings and Alerts

No rating or validation information has been found for pY011 (pcDNA3.1-hLb2Cpf1).

No alerts have been found for pY011 (pcDNA3.1-hLb2Cpf1).

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Chen P, et al. (2025) Highly parallel profiling of the activities and specificities of Cas12a variants in human cells. Nature communications, 16(1), 3022.

Zhou J, et al. (2022) Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Molecular therapy : the journal of the American Society of Gene Therapy, 30(1), 244.

Ou T, et al. (2022) Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire. Molecular therapy : the journal of the American Society of Gene Therapy, 30(1), 184.

Tran MH, et al. (2021) A more efficient CRISPR-Cas12a variant derived from Lachnospiraceae bacterium MA2020. Molecular therapy. Nucleic acids, 24, 40.